Xencor, Inc. (NASDAQ:XNCR) Shares Bought by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 22.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,040 shares of the biopharmaceutical company’s stock after buying an additional 7,040 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.06% of Xencor worth $897,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after acquiring an additional 78,066 shares during the period. Prudential Financial Inc. raised its position in Xencor by 10.7% in the fourth quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company’s stock worth $1,625,000 after acquiring an additional 6,810 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Xencor during the 4th quarter worth $632,000. Raymond James Financial Inc. acquired a new position in shares of Xencor during the 4th quarter worth $2,329,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Xencor by 16.5% in the fourth quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock valued at $7,817,000 after purchasing an additional 48,229 shares during the period.

Insider Buying and Selling

In other news, EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the transaction, the executive vice president now owns 49,169 shares of the company’s stock, valued at $542,334.07. This represents a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.76% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on XNCR shares. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. William Blair started coverage on shares of Xencor in a research report on Monday, April 21st. They issued an “outperform” rating on the stock. Finally, Barclays lowered their price objective on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research note on Thursday, May 8th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Xencor Price Performance

Xencor stock opened at $8.11 on Wednesday. The stock has a market capitalization of $577.04 million, a P/E ratio of -2.53 and a beta of 0.99. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm’s 50-day moving average is $10.63 and its two-hundred day moving average is $17.52.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. During the same quarter last year, the business posted ($1.11) EPS. The firm’s revenue was up 104.6% compared to the same quarter last year. Equities analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.